With a median follow-up of 27 months, 69% of patients were still alive and the progression-free survival (PFS) rate was 30%. Achieving a CR was associated with better PFS, with patients who ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback